79 results about "Artificial livers" patented technology

The invention discloses an implanted artificial liver comprising a polyglycolic acid or polylactic-co-glycolic acid sleeve, more than one three-dimensional porous scaffold, and polyglycolic acid or polylactic-co-glycolic acid tube seals; the three-dimensional porous scaffolds are mounted inside the polyglycolic acid or polylactic-co-glycolic acid sleeve; and polyglycolic acid or polylactic-co-glycolic acid tubes are used for sealing two ends of the polyglycolic acid or polylactic-co-glycolic acid sleeve. The invention has the beneficial effects of maximally simulating the structure of a hepatic lobule, developing implanted stem cells into liver cells through directional differentiation, and inducing the regeneration of microvessels of a tissue engineering liver. Meanwhile, the exterior of the three-dimensional porous scaffolds is wrapped in the highly biocompatible biomaterial sleeve which serves to simulate the structure of a liver capsule; and small lacunas are formed between the sleeve and the scaffolds to allow blood to circulate through tissue engineering brackets, thereby facilitating the regeneration of vessels of the engineering liver in an envelope, and ultimately forming an artificial liver to replace the damaged liver of a parasitifer.

A dialysis apparatus for treating a patient with liver and / or kidney disease. In one embodiment a liver dialysis apparatus comprises an artificial liver. The artificial liver comprises a blood compartment, a vegetable protein compartment, and a clear dialysis compartment. In another embodiment the liver dialysis apparatus comprises cartridge made up of at least one layer of vegetable protein. In a further embodiment of the invention a dialysate regeneration device is provided which comprises at least one layer of vegetable protein. The vegetable protein is preferably a soy protein. The soy protein may be unmodified soy protein with urease enzyme activity, modified soy protein with or without urease activity, alone or in combination.

Two cell lines, PICM-19H and PICM-19B, were derived from the bipotent ARS-PICM-19 pig liver stem cell line and assessed for their potential application in artificial liver devices. The study included assessments of growth rate and cell density in culture, morphological features, and hepatocyte detoxification functions, i.e., inducible CYP450 activity, ammonia clearance, and urea production. The PICM-19H cells contain numerous mitochondria, Golgi apparatus, smooth and rough endoplasmic reticulum, vesicular bodies and occasional lipid vacuoles. PICM-19H cells display inducible CYP450 activity, clear ammonia, and produce urea in a glutamine-free medium. Ultrastructural analysis of the PICM-19B monolayers show that the roughly cuboidal cells display basal-apical polarization and are joined by tight junction-like complexes. Other ultrastructure features are similar to those of PICM-19H cells except that they possess numerous cell bodies resembling mucus vacuoles. The PICM-19B cells possess relatively high levels of GGT activity, but retain some inducible CYP450 activity, and some ammonia clearance and urea synthesis ability. These data indicate that both cell lines, either together or alone, may be useful as the cellular substrate for an artificial liver device. In vitro models of the liver are needed to replace animal models for the rapid assessment of drug biotransformation and toxicity. A unipotent porcine stem cell line PICM-19H differentiates exclusively into hepatocytes and can be induced to express CYP450 enzymes. These cells have many activities associated with xenobiotic phase I and phase II metabolism lacking in other liver cell lines. The PICM-19H cell line was also compared to the tumor-derived human HepG2 C3A cell line and to primary cultures of adult porcine hepatocytes. The results demonstrate the potential for the use of PICM-19H cells in drug biotransformation and toxicity testing and further support their use in artificial liver device technology.

The object of the invention is to provide an apparatus used in a plasma exchange therapy, which is operable with only a minor modification to a conventional plasma exchange apparatus and wherein valuable plasma is not disposed but recycled as a dialysis solution. The present invention is related to an apparatus used in a plasma exchange therapy wherein at least a portion of separated plasma is purified and circulated as a dialysis solution to dialyze patient's blood to remove harmful substances contained in the plasma; a plasma exchange apparatus incorporating said apparatus; and an artificial liver equipped with these apparatuses.

The invention provides preparation of an animal model for screening hepatocyte growth-promoting regenerative medicines in fulminant liver function failure curing process and evaluating therapeutic effect of a tissue engineering liver supporting system or hepatic cell and stem cell transplantation by using amanitin and endotoxin lipopoly-saccharide, wherein an application method adopts single intraperitoneal instillation with dosage of 0.1mg / kg, and the dosage of the endotoxin is 1mug / kg. The invention further provides a method for preparing fulminant liver function failure and a fulminant liver function failure animal model prepared by the method. The animal model can be used for evaluation of biotechnological new drugs that a rodent animal model cannot accomplish, and can be used for the evaluation of tissue engineering liver, biological artificial liver, the hepatic cell and stem cell transplantation treatment technologies.

The invention discloses an apparatus adapted for artificial liver, which comprises a holding portion and a control portion, wherein the holding portion is a transparent container made of heat-insulating material equipped with peristaltic pump, a clip holder and conduit support bracket, the control component comprises an electric heater, a heating arrangement, a temperature control system and a control display screen.

Provided herein are cell compositions useful for making artificial liver constructs. The cell composition my include, in combination, (a) hepatocyte cells, (b) Kuppfer cells, (c) hepatic stellate cells, (d) sinusoidal endothelial cells, and (e) cholangiocyte cells.

The invention discloses a spiral hollow fiber tube artificial liver bioreactor. A plurality of hollow fiber tubes are evenly packed in parallel in the center of the transparent cylindrical container. The inside of the hollow fiber tube is the inner cavity, and the outside of the hollow fiber tube is the outer cavity. The patient plasma / blood inlet and patient plasma / blood outlet of the inner cavity are respectively set. At both ends of the cylindrical container, the inlet of the hepatic cell culture solution and the outlet of the hepatic cell culture solution in the outer cavity are arranged side by side on the cylindrical surface of the cylindrical container. The plurality of hollow fiber tubes are a plurality of helical hollow fiber tubes, and the helix angle is not more than 45° and not less than 10°. The invention ensures that there is enough area for the hepatocytes to adhere to the wall and grow, and at the same time, the blood flow in the spiral tube will generate a secondary flow, which is conducive to the full mixing of blood and prevents a large amount of plasma protein from adhering to the tube wall to block the holes of the hollow fiber membrane. It is helpful for the detoxification and mass transfer of the hollow fiber, prolongs the supporting time of the artificial liver in vitro, and improves the therapeutic efficiency of the artificial liver.

The invention discloses a semipermeable membrane layered bio-artificial liver online monitoring and constant-temperature heating integrated system, which comprises a blood input port, a blood pump, an arterial kettle, a semipermeable membrane layered integrated bioreactor, an intravenous kettle and a blood return port which are sequentially connected; the semipermeable membrane layered integrated bioreactor comprises a cavity, a plasma separator which is arranged at one side of the cavity and a bio-reactor body which is arranged at the other side of the cavity; the plasma separator and the bio-reactor body are spaced by virtue of a spacing semipermeable membrane; and multiple layers of filtering semipermeable membranes are horizontally arranged in the bio-reactor body. The integrated system disclosed by the invention has the beneficial effects that the integrated system is simpler and more practical in design; cells and plasma get into full contact, which is conducive to improving an exchange efficiency of the two types of substances, and a plasma degrading effect is enhanced; a cell storage space is enlarged and a loading capacity is increased.